Italia markets closed

Dynavax Technologies Corporation (0IDA.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
14,36-0,41 (-2,79%)
Alla chiusura: 05:23PM BST
Schermo intero
Chiusura precedente14,77
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno14,36 - 14,90
Intervallo di 52 settimane9,50 - 15,11
Media Volume520
Beta (5 anni mensile)1,52
Rapporto PE (ttm)0,19
EPS (ttm)0,75
Prossima data utili01 nov 2023 - 06 nov 2023
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023

    -- China commercial launch in multiple provinces and municipalities expected to begin in Q1 2023, and Clover anticipates a significant and sustained long-term annual booster market for its premium, broadly protective protein-based COVID-19 vaccines in China -- -- SCB-2019 (CpG 1018/Alum) anticipated to receive emergency use authorization (EUA) in at least one additional country and to complete multiple EUA submissions during H1 2023, with commercial value driven via bilateral supply agreements e

  • GlobeNewswire

    Clover’s Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infectious Diseases

    -- The study, a collaboration between Clover and the International Vaccine Institute, showed that a household contact was 84% less likely to get a SARS-CoV-2 infection when the infected household member had received SCB-2019 (CpG 1018/Alum) compared to placebo -- -- Results indicate that vaccination with SCB-2019 can potentially help control the spread of SARS-CoV-2 within communities through the reduction of transmission to household contacts and through previously demonstrated efficacy against

  • GlobeNewswire

    Clover Provides Update on 2022 Corporate Milestones

    -- Significant progress made on regulatory submissions to the China NMPA, the EMA, and the WHO for Clover’s lead COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum), with completion anticipated in Q4 2022 -- -- New data demonstrating superiority as a heterologous booster compared to inactivated vaccine, robust neutralization of globally dominant Omicron BA.5 strain, and 84% reduction in transmission of SARS-CoV-2 infection to household contacts -- -- Clover poised to become a unique, integrated